App-Quantinova.ai

Peri-operative management of anticoagulation and bleeding in patients undergoing Catheter Directed Thrombolysis for acute iliofemoral Deep Vein Thrombosis

K. White - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Deep vein thrombosis

N/A

Pim kinase: A novel regulator of platelet and megakaryocyte thromboxane A2 and C-X-C-R motif receptors

S. Nock - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

AZD-1208

Platelet count as a novel diagnostic marker for early lung cancer diagnosis: an epidemiological study

M. Barlow - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability

J. Mitchell - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Platelet generation from circulating megakaryocytes is triggered in the lung vasculature

X. Zhao - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Platelet glycoprotein analysis by flow cytometry, could further diagnostic information be gained from the mean fluorescence intensity values?

A. McCormick - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Platelet RalA/B play pivotal roles in regulation of venous thrombosis by co-ordinating P-selectin-HMGB1 interaction

Y. Li - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Platelet transfusion better preserves ROTEM clot strength and thrombin generation: a case-control study

A. Rossetto - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

cytochalasin D

Platelet-released mitochondria interact with neutrophils, altering their phenotype and merging with the existing mitochondrial network

H. Allan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Twin-reversed arterial perfusion

N/A

Pooled analysis of long-term efficacy and safety of simoctocog alfa in previously treated patients with haemophilia A

M. Mathias - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

simoctocog alfa

Post-partum Acquired Haemophilia A in the COVID era – building the case for Emicizumab?

C. Crossette-Thambiah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hemophilia

Oraprine

Post-thrombotic syndrome in patients with venous thromboembolism treated with rivaroxaban – Results from the FIRST Registry

V. Speed - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Practical utilisation of Octapharma FVIII concentrates in previously untreated and minimally treated haemophilia A patients entering routine clinical treatment – The Protect-NOW Study

S. Halimeh - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Pre-analytical screening and removal of Argatroban interference for Haemostasis assays

S. Cox-Morton - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Argatroban

Precision of One-Stage Clotting Factor Assays is Improved by Using Fresh Rather Than Stored Calibration Curves

N. Yartey - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

CS2100

Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors

D. Verhoef - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Predictors of venous thromboembolism in hospitalised COVID-19 positive patients

P. MacCallum - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Preference for ravulizumab over eculizumab: a real-world patient preference and life impact study on the treatment of atypical hemolytic uremic syndrome

T. Mauch - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Atypical hemolytic uremic syndrome

Eculizumab

Prevalence and Severity of Bleeding Events in Thrombotic Antiphospholipid Syndrome – Should They be Included in the Damage Index for Antiphospholipid Syndrome?

P. Gaspar - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

N/A

Procoagulant platelets have a distinct transcriptome that identifies the large GTPase dynamin as a driver in their formation

I. Tohidi-Esfahani - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Evithrom

Filters

45280 Abstracts